Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines segment, accounting for over 40% of sales, grew 14% in H1 2026 driven by HIV, respiratory, and oncology products. The company is accelerating R&D with over 20 phase III starts planned for 2026. However, GSK faces a significant challenge as dolutegravir patents expire in 2028-2029, threatening its HIV franchise which generated £2.74 billion in H1 2026. GSK is relying on long-acting HIV injectables and next-generation pipeline products to offset future generic competition.

Astrazeneca Secures FDA Approval for New Breast Cancer Treatment

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.

Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

Merck's stock is trading near its 52-week high, driven by positive phase III data for its Keytruda-Moderna cancer therapy combo and strong fundamentals. Keytruda is expected to reach $35 billion in peak sales by 2028, with the company launching 20 new drugs by 2030. However, Merck faces significant headwinds including Keytruda's 2028 patent expiration, declining Gardasil vaccine sales, and generic erosion of diabetes and other drugs.

3 Dividend Kings You Can Buy and Never Sell

The article highlights three Dividend King stocks (companies with 50+ consecutive years of dividend increases) as ideal long-term holdings: Coca-Cola, Federal Realty Investment Trust, and Consolidated Edison. Coca-Cola maintains market dominance with 64 years of dividend growth and 27% YTD gains. Federal Realty is the only REIT with Dividend King status, showing strong occupancy and 59 years of dividend increases. Consolidated Edison provides stable utility income with 52 years of dividend growth, benefiting from rising power demand.

JP Morgan Maintains Overweight on Federal Realty Investment, Raises Price Target to $129

Meet the Dividend King Stock That Yields Quadruple the S&P 500. Here's Why It's a Buy Now.

Federal Realty Investment Trust (FRT), the only REIT to achieve Dividend King status with 59 consecutive years of dividend growth, offers a nearly 4% forward dividend yield—quadruple the S&P 500's ~1%. The REIT's focus on high-quality retail properties in premium markets, strong occupancy rates (93.8%), and sustainable dividend policy (61-62% payout ratio) position it for both income generation and long-term capital appreciation, though recent dividend growth has slowed due to interest rate pressures.